ARTICLE SUMMARY:
Devices for deep venous disease are having their day; the markets are becoming crowded. Second-generation movers must now find meaningful ways to differentiate themselves. MedTech Strategist interviews two companies with outside-the-box solutions: SonoVascular, in venous thrombectomy, and Auxetics, the developer of a novel venous stent. Part 2 of a 2-part review of the deep venous device market.
Competition is intensifying in the device market for the treatment of venous thromboembolism (VTE). When it comes to thrombectomy, the largest category in the segment, first-movers Inari Medical, Penumbra Medical, Boston Scientific, and Thrombolex are operating in a $5.8 billion market ($2.8 billion for pulmonary embolism [PE] and $3 billion for deep vein thrombosis [DVT]) that is still largely unpenetrated (see Figures 1 and 2). During its investor presentation in February, Inari Medical, the leader in the space, estimated a total addressable market of $10 billion, across PE, DVT, chronic venous disease, dialysis access management, acute limb ischemia, and chronic limb ischemia. Venous stents represented a $1.03 billion market in 2023, based on three companies whose products offer very little differentiation, another large opportunity.
